Paion AG

PA8 · F

0.046EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.046

Open0.046

Day Range0.046 – 0.046

52-Week Range0.011 – 0.23

Volume0

Market Cap46.24M

P/E (TTM)0.00

Forward P/E72.46

EPS-0.03

Dividend Yield0.00%

Beta1.43

50-Day Avg0.0219

200-Day Avg0.0145

About

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Company Details

CEODr. James Neil Phillips ChB, M.B.A., M.D., MB, MBA
Employees70
HeadquartersHeussstrasse 25, Aachen, Germany, 52078, Germany
Websitehttps://www.paion.com

Leadership

Dr. James Neil Phillips ChB, M.B.A., M.D., MB, MBACEO & Chairman of Management Board · b. 1962
Mr. Sebastian WernerMember of Management Board & CFO
Ralf PennerVP of Investor Relations & PR
Dr. Shaw SorooshianSr. VP of Medical Affairs · b. 1964
Dr. Thomas StoehrSr. VP of Devel.

Financials

Income Statement

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Total Revenue	4.23M	3.46M	71.61K	4.26M	5.81M	2.77M	8.00M	19.66M	7.13M	33.25M
Growth (%)	-	-18.26%	-97.93%	+5851.03%	+36.36%	-52.40%	+189.24%	+145.69%	-63.73%	+366.42%
Cost of Revenue	0	4.15K	10.94K	0	0	0	-	-	3.08M	1.96M
Gross Profit	4.23M	3.45M	60.67K	4.26M	5.81M	2.77M	8.00M	19.66M	4.05M	31.29M
Gross Margin	100.00%	99.88%	84.72%	100.00%	100.00%	100.00%	100.00%	100.00%	56.83%	94.10%
Operating Expense	7.39M	15.50M	35.06M	29.34M	21.68M	15.22M	17.33M	18.07M	26.07M	29.78M
Operating Income	-3.16M	-12.04M	-35.00M	-25.08M	-15.87M	-12.46M	-9.33M	1.58M	-22.01M	1.50M
Operating Margin	-74.83%	-348.54%	-48866.15%	-588.54%	-273.13%	-450.31%	-116.57%	8.05%	-308.84%	4.53%
EBITDA	-	-	-	-	-15.52M	-12.20M	-9.21M	1.94M	-18.82M	4.31M
EBITDA Margin	-	-	-	-	-267.16%	-441.07%	-115.08%	9.85%	-264.08%	12.96%
Net Income	-2.21M	-9.10M	-28.21M	-20.12M	-12.09M	-9.94M	-7.02M	2.22M	-21.79M	-579.00K
Net Income Margin	-52.32%	-263.46%	-39395.04%	-472.05%	-208.11%	-359.36%	-87.70%	11.31%	-305.62%	-1.74%
R&D	4.58M	11.80M	29.38M	23.41M	17.85M	12.17M	13.10M	10.29M	5.25M	6.49M
R&D as % of Total Revenue	108.41%	341.43%	41032.20%	549.26%	307.23%	439.90%	163.74%	52.34%	73.63%	19.50%
Interest Expense	0	0	0	0	0	0	123.39K	162.92K	2.07M	2.80M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.54%	0.83%	28.97%	8.43%

Balance Sheet

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Total Assets	18.02M	66.55M	43.47M	37.98M	31.89M	24.32M	24.91M	28.15M	36.78M	38.18M
Total Liabilities	4.69M	3.94M	7.91M	13.04M	6.66M	3.50M	10.18M	6.86M	29.79M	31.56M
Total Equity	13.33M	62.61M	35.56M	24.94M	25.23M	20.82M	14.73M	21.29M	7.00M	6.62M
Cash	13.29M	58.91M	32.68M	30.11M	24.84M	17.23M	18.79M	19.67M	6.44M	10.63M
Net Debt	-	-	-	-	-	-	-	-	13.04M	9.12M

Cash Flow

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Operating Cash Flow	-1.75M	-12.04M	-26.29M	-11.59M	-17.72M	-12.81M	-2.85M	906.13K	-21.18M	5.94M
Investing Cash Flow	-5.24K	-26.47K	-33.48K	-192.14K	-24.98K	-13.07K	-14.24K	-13.68K	-19.21M	-
Financing Cash Flow	-7.16M	57.62M	22.05K	9.21M	12.49M	5.21M	4.41M	-24.46K	27.15M	-
Capital Expenditure	5.24K	26.47K	33.48K	198.86K	24.98K	13.07K	15.26K	13.68K	19.21M	1.59M
Free Cash Flow	-	-	-	-	-17.75M	-12.83M	-2.86M	892.44K	-40.38M	4.36M
FCF to OCF	-	-	-	-	100.14%	100.10%	100.54%	98.49%	190.68%	73.30%

Earnings

Report Date	Nov 9, 2016	May 10, 2017	Aug 9, 2017	Nov 8, 2017	Mar 22, 2018	May 9, 2018	Aug 8, 2018	Nov 7, 2018	Mar 20, 2019	May 8, 2019	Aug 7, 2019	Nov 6, 2019	Mar 26, 2020	May 13, 2020	Aug 12, 2020	Nov 11, 2020	Mar 30, 2021	Apr 16, 2021	Aug 23, 2021	Nov 10, 2021	Mar 30, 2022	May 19, 2022	Aug 31, 2022	Nov 15, 2022	Mar 30, 2023	May 17, 2023	Sep 29, 2023	Nov 15, 2023	Mar 28, 2024	May 8, 2024	Aug 7, 2024	Nov 29, 2024	Mar 27, 2025	May 30, 2025	Sep 3, 2025	Nov 28, 2025	Apr 2, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Actual	-0.05	0.00	-0.10	0.00	-0.10	0.00	-0.10	0.00	-0.06	0.00	0.01	0.00	-0.07	0.00	-0.06	0.00	0.13	-0.05	-0.09	0.00	0.00	0.21	-0.07	0.00	0.00	0.00	-0.60	0.00	0.00	0.00	0.00	0.00	-0.63	0.00	0.00	0.00	0.00
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.48%	-	-	-	-	-	-	-	-	-	-
Timing	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	After-hours	Pre-market	Pre-market	After-hours	Pre-market	After-hours	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap46.24M

Enterprise Value94.83K

Trailing P/E0.00

Forward P/E72.46

PEG Ratio0.00

Price / Sales0.00

Price / Book2.84

EPS-0.03

Book Value0.927

Revenue (TTM)33.25M

Gross Profit (TTM)31.75M

EBITDA3.23M

Profit Margin-1.74%

Operating Margin6.68%

Return on Equity-8.51%

Return on Assets3.70%

Shares Outstanding7.13M

Shares Float6.48M

Beta1.43

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Apr 12, 20231:10